Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? HemaSphere Myelodysplastic Syndromes (MDS)
Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis Blood Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT Blood Aplastic Anemia
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial Lancet Haematology Myelodysplastic Syndromes (MDS)
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes Lancet Haematology Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Lancet Hematology Myelodysplastic Syndromes (MDS)
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors PLOS One Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica Aplastic Anemia

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Research